Abstract
Abstract
Introduction
Although the growing treatment landscape for metastatic prostate cancer (mPC) has revealed new opportunities, it has also provided challenges, such as undesirable side effects. The aim of the present study was to provide further data on domain-specific cognitive impairments in mPC patients with androgen deprivation therapy (ADT) and new hormonal agents.
Methods
Fifty-eight patients (71 ± 8 years) with mPC were investigated using a cross-sectional design. All patients had received some form of ADT (93% had received luteinizing hormone-releasing hormone (LHRH) analogs/antagonists), 66% had received chemotherapy, and 84% had received anti-resorptive therapy. We evaluated learning and memory, processing speed, and executive functions, as recommended by the International Cognition and Cancer Task Force, to determine neurocognitive deficits.
Results
Patients treated with ADT scored significantly lower on all neurocognitive tests and showed significantly more neurocognitive deficits (38–62%) than age-adjusted reference samples (16%, p < 0.05). Cognitive deficits were mild in most cases and predominantly affected visuomotor processing speed (48%). Moderate and severe deficits were found in 11% and 5% of patients, respectively, with word fluency as the predominant deficit (23%). No associations were found between the type or duration of treatment and the severity of cognitive deficits.
Conclusions
Treatment of mPC with ADT is correlated with neurocognitive deficits in several cognitive domains. Language skills and processing speed were most frequently impaired. However, a consistent pattern of cognitive impairment was not identified. Neurocognitive deficits should be considered in phase III and IV trials.
Trial registration
The study was registered in the German Clinical Trials Registry (DRKS00017727).
Funder
Universitätsklinikum Heidelberg
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS (2019) Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 17(5):479–505
2. D’Aniello C, Cavaliere C, Foglia C, Facchini S, Uricchio F, Balsamo R, Franzese E, De Falco S, Izzo M, Laterza M (2022) Management of systemic prostate cancer: current algorithm from castration sensitive to castration resistant setting. J Eur Rev Med Pharmacol Sci 26(22):8481–8501
3. Staat K, Segatore M (2005) The phenomenon of chemo brain. Clin J Oncol Nurs 9(6):713–721
4. Treanor C, Li J, Donnelly M (2017) Cognitive impairment among prostate cancer patients: an overview of reviews. Eur J Cancer Care 26(6):e12642
5. Horowitz TS, Suls J, Treviño M (2018) A call for a neuroscience approach to cancer-related cognitive impairment. Trends Neurosci 41(8):493–496
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献